Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

S&P Global

Sysco

As someone who has been actively investing for several years, I can tell you that it's natural to be drawn to thrilling investment opportunities promising impressive returns. However, I've learned that while the appeal of these opportunities is strong, embracing the stability of “boring” stocks often proves to be the wiser course of action.

Boring Is Beautiful: 3 Blue-Chip Stocks to Buy and Hold Forever

Blackrock Inc

Evergy Inc

Microsoft

I started a dividend growth portfolio in 2008 and have seen steady increases in dividends over the years. The portfolio has also delivered sizable total returns. The portfolio is focused on dividend growth stocks that increase their dividends every year, and with dividends that are reinvested to improve returns. The portfolio is managed according to a business plan that embodies best practices for this type of portfolio, developed over the years.

16 Years As A Dividend Growth Investor: Challenges, Opportunities And A Look Ahead

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech. Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of.

Johnson & Johnson Completes Acquisition of Shockwave Medical

Johnson & Johnson (JNJ) closed the most recent trading day at $145.28, moving +0.58% from the previous trading session.

Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts

Merck

Pfizer

CNBC will be on the ground at the ASCO annual meeting in Chicago. Meanwhile, Epic released a free tool set to help health systems evaluate AI models.

Healthy Returns: Pfizer, Merck, J&J and more to release cancer drug data at industry conference

Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

NEW YORK , May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

Sarepta Therapeutics Set to Join S&P MidCap 400

Johnson & Johnson (NYSE:JNJ ) Bernstein's 40th Annual Strategic Decisions Conference Call May 29, 2024 1:30 PM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright Okay. Thanks, everybody.

Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)

J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.

J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate

Johnson & Johnson said on Wednesday its experimental therapy, seltorexant, met all main and secondary goals in a late-stage study evaluating it in patients with major depressive disorder (MDD) and insomnia symptoms.

J&J's treatment for depression succeeds in late stage study

Intuitive Surgical

Stryker

While the biotechnology sector may receive most of the attention under the broad healthcare umbrella, investors ought to spare some love for medical technology stocks. The enterprises undergirding these securities offer tremendously positive potential for overall patient outcomes.

HealthTech Heroes: 3 Medical Technology Stocks to Buy Before They Boom

Johnson & Johnson said on Tuesday it had agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for about $1.25 billion.

J&J acquires rights to skin disorder drug for $1.25 bln

Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing a pipeline of immunology and oncology therapeutics, to acquire from Numab's shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion. NM26, which is ready to en.

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

Comcast

Dow Inc

Duke Energy

Kinder Morgan

Medtronic

Altria

PNC Financial Services

SPDR S&P 500 ETF Trust

Sempra Energy

Verizon

Morningstar published their 10 Best Dividend Stocks, which are undervalued blue-chip stocks with reliable dividends. The article analyzes the valuation and estimated future total return of each stock, comparing them to the S&P 500. Comcast has the highest potential rate of return among the 10 stocks, while Sempra has the lowest.

Going Beyond Morningstar's 10 Best Dividend Stocks List

American Express

PepsiCo

Dividend investment can make you wealthy but you need to pick the right stocks. Whether you are just beginning your investment journey or are a professional at it, there is nothing better than receiving income without having to work for it.

7 Dividend Stocks That Could Soar After Q1 Earnings Reports

Cisco Systems

Intel

With the Dow Jones Industrial Average down 2% so far over the week of May 20, all of the Dow 30 stocks have taken a dip. For the average layman, this means the broader stock market contracted this week, but most professional investors would defer to the S&P 500 which is down an average of 0.74% in the same timeframe.

3 Dow Stocks to Buy on the Dip: May 2024

Amcor Plc

Brookfield Asset Management

Brookfield Renewable Partners

Blackstone Secured Lending Fund

Chevron

Con Ed

Enterprise Products Partners

Federal Realty Investment Trust

Coca-Cola

NextEra Energy

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

W. P. Carey

Dividend Aristocrats are generally excellent stocks for a retiree's passive income portfolio. They generally have wide moats, strong balance sheets, excellent management teams, and the ability to navigate all sorts of economic environments. We provide a diversified portfolio of 10 Dividend Aristocrats that have the potential to fund living expenses indefinitely and grow at a rate that beats inflation.

If I Had To Retire With 10 Dividend Aristocrats, It Would Be These

McDonald's

Restaurant Brands

In today's uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty.

3 Stocks to Safeguard Your Investments During a Market Meltdown

A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer.

News for Johnson & Johnson Stock (JNJ)